---
layout: default
title: Brivaracetam
description: "Brivaracetam çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 34
evidence_level: L3
indication_count: 10
---

# Brivaracetam

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Brivaracetamï¼šå¾å±€éƒ¨ç™²ç™‡åˆ°è¦–è¦ºæ€§ç™²ç™‡

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Brivaracetam å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Brivaracetam åŸç‚ºæ²»ç™‚å±€éƒ¨ç™²ç™‡ç™¼ä½œçš„ç¬¬ä¸‰ä»£æŠ—ç™²ç™‡è—¥ç‰©ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°è¦–è¦ºæ€§ç™²ç™‡(visual epilepsy)æœ‰æ²»ç™‚æ½›åŠ›ã€‚
</p>

## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | 1å€‹æœˆå¤§ä»¥ä¸Šå±€éƒ¨ç™²ç™‡ç™¼ä½œç—…äººçš„æ²»ç™‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | visual epilepsyã€status epilepticusã€partial epilepsyã€eating seizuresã€orgasm-induced seizuresã€thinking seizuresã€startle epilepsyã€micturation-induced seizuresã€audiogenic seizuresã€beta-ketothiolase deficiency |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.51% |
| è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶/å…‰æ•æ„Ÿæ€§ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 3å¼µ |
| å»ºè­°æ±ºç­– | Proceed |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. visual epilepsy</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.51%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Brivaracetam æ˜¯ levetiracetam çš„çµæ§‹é¡ä¼¼ç‰©ï¼Œå…·æœ‰ç¨ç‰¹çš„ä½œç”¨æ©Ÿè½‰ï¼š</p>

<ol>
<li><strong>SV2A é«˜è¦ªå’ŒåŠ›çµåˆ</strong>ï¼šbrivaracetam å°çªè§¸å›Šæ³¡è›‹ç™½ 2A (SV2A) çš„è¦ªå’ŒåŠ›æ˜¯ levetiracetam çš„ 15-30 å€</li>
<li><strong>å¿«é€Ÿè…¦éƒ¨ç©¿é€</strong>ï¼šé«˜è„‚æº¶æ€§ä½¿å…¶èƒ½å¿«é€Ÿé€²å…¥ä¸­æ¨ç¥ç¶“ç³»çµ±</li>
<li><strong>å…‰æ•æ„Ÿæ€§ç™²ç™‡ç ”ç©¶</strong>ï¼šå·²æœ‰è‡¨åºŠç ”ç©¶è­‰å¯¦ brivaracetam èƒ½æŠ‘åˆ¶å…‰åˆºæ¿€èª˜ç™¼çš„è…¦é›»åœ–ç•°å¸¸åæ‡‰ (PPR)</li>
<li><strong>å»£è­œæŠ—ç™²ç™‡æ´»æ€§</strong>ï¼šå‰è‡¨åºŠç ”ç©¶é¡¯ç¤ºå°å¤šç¨®ç™²ç™‡æ¨¡å‹æœ‰æ•ˆ</li>

</ol>
<p>è¦–è¦ºæ€§ç™²ç™‡èˆ‡å…‰æ•æ„Ÿæ€§ç™²ç™‡ç›¸é—œï¼Œbrivaracetam åœ¨æ­¤é ˜åŸŸå·²æœ‰åˆæ­¥è‡¨åºŠè­‰æ“šæ”¯æŒã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37684052/" target="_blank">37684052</a></td><td>2023</td><td>Article</td><td>BMJ (Clinical research ed.)</td><td>Management of epilepsy during pregnancy and lactation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38811492/" target="_blank">38811492</a></td><td>2024</td><td>Article</td><td>Advances in therapy</td><td>Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38117319/" target="_blank">38117319</a></td><td>2024</td><td>Article</td><td>Intensive care medicine</td><td>Status epilepticus in the ICU.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31033711/" target="_blank">31033711</a></td><td>2019</td><td>Article</td><td>JAAPA : official journal of th</td><td>Brivaracetam for epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38576178/" target="_blank">38576178</a></td><td>2024</td><td>Article</td><td>Epilepsia open</td><td>Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36218253/" target="_blank">36218253</a></td><td>2022</td><td>Article</td><td>Revista de neurologia</td><td>[Paediatric status epilepticus].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32120063/" target="_blank">32120063</a></td><td>2020</td><td>Article</td><td>Neuropharmacology</td><td>Mechanisms of action of currently used antiseizure drugs.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26760311/" target="_blank">26760311</a></td><td>2016</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Brivaracetam for the treatment of epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37350392/" target="_blank">37350392</a></td><td>2023</td><td>Article</td><td>Epilepsia</td><td>Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31195850/" target="_blank">31195850</a></td><td>2019</td><td>Article</td><td>Expert review of neurotherapeu</td><td>Brivaracetam efficacy and safety in focal epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33479851/" target="_blank">33479851</a></td><td>2021</td><td>Article</td><td>CNS drugs</td><td>Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Futur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21682662/" target="_blank">21682662</a></td><td>2011</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Brivaracetam for the treatment of epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32822230/" target="_blank">32822230</a></td><td>2020</td><td>Article</td><td>Epilepsy currents</td><td>Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35285519/" target="_blank">35285519</a></td><td>2022</td><td>Article</td><td>The Cochrane database of syste</td><td>Brivaracetam add-on therapy for drug-resistant epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37483441/" target="_blank">37483441</a></td><td>2023</td><td>Article</td><td>Frontiers in neurology</td><td>Safety and efficacy of brivaracetam in children epilepsy: a systematic review an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31937513/" target="_blank">31937513</a></td><td>2020</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36842341/" target="_blank">36842341</a></td><td>2023</td><td>Article</td><td>Journal of the neurological sc</td><td>Epilepsy and brain tumors: Two sides of the same coin.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32966640/" target="_blank">32966640</a></td><td>2021</td><td>Article</td><td>Acta neurologica Scandinavica</td><td>Potential role of brivaracetam in pediatric epilepsy.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. status epilepticus</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07163572" target="_blank">NCT07163572</a></td><td>NA</td><td>COMPLETED</td><td>152</td><td>Safety and Efficacy of Intravenous Brivaracetam Versus Levetiracetam in the Mana...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ19 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38117319/" target="_blank">38117319</a></td><td>2024</td><td>Article</td><td>Intensive care medicine</td><td>Status epilepticus in the ICU.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32278203/" target="_blank">32278203</a></td><td>2020</td><td>Article</td><td>Journal of the neurological sc</td><td>Efficacy and tolerability of intravenous brivaracetam for status epilepticus: A ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37350392/" target="_blank">37350392</a></td><td>2023</td><td>Article</td><td>Epilepsia</td><td>Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36218253/" target="_blank">36218253</a></td><td>2022</td><td>Article</td><td>Revista de neurologia</td><td>[Paediatric status epilepticus].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39899098/" target="_blank">39899098</a></td><td>2025</td><td>Article</td><td>Continuum (Minneapolis, Minn.)</td><td>First Seizures, Acute Repetitive Seizures, and Status Epilepticus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32822230/" target="_blank">32822230</a></td><td>2020</td><td>Article</td><td>Epilepsy currents</td><td>Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26891946/" target="_blank">26891946</a></td><td>2016</td><td>Article</td><td>Expert review of clinical phar</td><td>Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31264486/" target="_blank">31264486</a></td><td>2019</td><td>Article</td><td>Expert opinion on pharmacother</td><td>Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30530123/" target="_blank">30530123</a></td><td>2019</td><td>Article</td><td>Epilepsy research</td><td>Intravenous brivaracetam in status epilepticus: Correlation between loading dose...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32480279/" target="_blank">32480279</a></td><td>2020</td><td>Article</td><td>Seizure</td><td>Brivaracetam in absence status epilepticus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30473267/" target="_blank">30473267</a></td><td>2019</td><td>Article</td><td>Seizure</td><td>Novel drugs and early polypharmacotherapy in status epilepticus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31342405/" target="_blank">31342405</a></td><td>2019</td><td>Article</td><td>CNS drugs</td><td>Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19941524/" target="_blank">19941524</a></td><td>2009</td><td>Article</td><td>Epilepsia</td><td>What is the promise of new antiepileptic drugs in status epilepticus? Focus on b...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36528008/" target="_blank">36528008</a></td><td>2023</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>Brivaracetam or levetiracetam in status epilepticus?: Lessons from the photosens...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37839249/" target="_blank">37839249</a></td><td>2023</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>The real-world effectiveness of intravenous brivaracetam as a second-line treatm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33561784/" target="_blank">33561784</a></td><td>2021</td><td>Article</td><td>Seizure</td><td>Intravenous brivaracetam in status epilepticus: A multicentric retrospective stu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31260101/" target="_blank">31260101</a></td><td>2019</td><td>Article</td><td>Epilepsia</td><td>Use of intravenous brivaracetam in status epilepticus: A multicenter registry.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28427029/" target="_blank">28427029</a></td><td>2017</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>Treatment of refractory and super-refractory status epilepticus with brivaraceta...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30043427/" target="_blank">30043427</a></td><td>2018</td><td>Article</td><td>Epilepsia</td><td>Intravenous brivaracetam in status epilepticus: A retrospective single-center st...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. eating seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. orgasm-induced seizures</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. thinking seizures</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38558319/" target="_blank">38558319</a></td><td>2024</td><td>Article</td><td>Neurological sciences : offici</td><td>Brivaracetam use in clinical practice: a Delphi consensus on its role as first a...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. startle epilepsy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. micturation-induced seizures</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ18 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38117319/" target="_blank">38117319</a></td><td>2024</td><td>Article</td><td>Intensive care medicine</td><td>Status epilepticus in the ICU.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38576178/" target="_blank">38576178</a></td><td>2024</td><td>Article</td><td>Epilepsia open</td><td>Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian pat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39899098/" target="_blank">39899098</a></td><td>2025</td><td>Article</td><td>Continuum (Minneapolis, Minn.)</td><td>First Seizures, Acute Repetitive Seizures, and Status Epilepticus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36218253/" target="_blank">36218253</a></td><td>2022</td><td>Article</td><td>Revista de neurologia</td><td>[Paediatric status epilepticus].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37684052/" target="_blank">37684052</a></td><td>2023</td><td>Article</td><td>BMJ (Clinical research ed.)</td><td>Management of epilepsy during pregnancy and lactation.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35861924/" target="_blank">35861924</a></td><td>2022</td><td>Article</td><td>CNS drugs</td><td>Antiseizure Drugs and Movement Disorders.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36194365/" target="_blank">36194365</a></td><td>2022</td><td>Article</td><td>CNS drugs</td><td>Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33839453/" target="_blank">33839453</a></td><td>2021</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33479851/" target="_blank">33479851</a></td><td>2021</td><td>Article</td><td>CNS drugs</td><td>Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Futur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32120063/" target="_blank">32120063</a></td><td>2020</td><td>Article</td><td>Neuropharmacology</td><td>Mechanisms of action of currently used antiseizure drugs.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38811492/" target="_blank">38811492</a></td><td>2024</td><td>Article</td><td>Advances in therapy</td><td>Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37350392/" target="_blank">37350392</a></td><td>2023</td><td>Article</td><td>Epilepsia</td><td>Diagnosing nonconvulsive status epilepticus: Defining electroencephalographic an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32822230/" target="_blank">32822230</a></td><td>2020</td><td>Article</td><td>Epilepsy currents</td><td>Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35061214/" target="_blank">35061214</a></td><td>2022</td><td>Article</td><td>Drugs</td><td>Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38643679/" target="_blank">38643679</a></td><td>2024</td><td>Article</td><td>Seizure</td><td>A comparison of cenobamate with other newer antiseizure medications for adjuncti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31603844/" target="_blank">31603844</a></td><td>2019</td><td>Article</td><td>Medicina</td><td>[New antiepileptic drugs].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39948216/" target="_blank">39948216</a></td><td>2025</td><td>Article</td><td>European journal of clinical p</td><td>Adjunctive treatment for pediatric focal epilepsy: a systematic review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31033711/" target="_blank">31033711</a></td><td>2019</td><td>Article</td><td>JAAPA : official journal of th</td><td>Brivaracetam for epilepsy.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. audiogenic seizures</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18500360/" target="_blank">18500360</a></td><td>2008</td><td>Article</td><td>British journal of pharmacolog</td><td>Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a hig...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21575627/" target="_blank">21575627</a></td><td>2011</td><td>Article</td><td>European journal of pharmacolo</td><td>Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26663401/" target="_blank">26663401</a></td><td>2016</td><td>Article</td><td>Epilepsia</td><td>Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligan...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39827675/" target="_blank">39827675</a></td><td>2025</td><td>Article</td><td>Epilepsy &amp; behavior : E&amp;B</td><td>A multicenter Phase II randomized, placebo-controlled single-blind trial with th...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20102365/" target="_blank">20102365</a></td><td>2010</td><td>Article</td><td>Basic &amp; clinical pharmacology </td><td>Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction o...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17785672/" target="_blank">17785672</a></td><td>2007</td><td>Article</td><td>Neurology</td><td>Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18552880/" target="_blank">18552880</a></td><td>2008</td><td>Article</td><td>British journal of pharmacolog</td><td>Brivaracetam: a rational drug discovery success story.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32949370/" target="_blank">32949370</a></td><td>2020</td><td>Article</td><td>CNS drugs</td><td>Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetira...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14736235/" target="_blank">14736235</a></td><td>2004</td><td>Article</td><td>Journal of medicinal chemistry</td><td>Discovery of 4-substituted pyrrolidone butanamides as new agents with significan...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. beta-ketothiolase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.14%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. adolescent/adult onset autosomal dominant epilepsy with auditory features</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
Brivaracetam åœ¨å°ç£çš„è—¥å“è¨±å¯è­‰ï¼š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… |
|-----------|--------|------|-------------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027714è™Ÿ | å¿…æ²»ç™²è†œè¡£éŒ  10mg | è†œè¡£éŒ  | å°ç£å„ªæ™‚æ¯”è²¿æ˜“æœ‰é™å…¬å¸ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027714è™Ÿ | å¿…æ²»ç™²è†œè¡£éŒ  25mg | è†œè¡£éŒ  | å°ç£å„ªæ™‚æ¯”è²¿æ˜“æœ‰é™å…¬å¸ |
| è¡›éƒ¨è—¥é™¸è¼¸å­—ç¬¬001179è™Ÿ | ä¸é†¯èƒºå¡å’¯é…®(åŸæ–™è—¥) | ç²‰æœ« | ä¸æ³°ä¼æ¥­æœ‰é™å…¬å¸ |

æ ¸å‡†é©æ‡‰ç—‡ï¼šé©ç”¨æ–¼1å€‹æœˆå¤§ä»¥ä¸Šå±€éƒ¨ç™²ç™‡ç™¼ä½œç—…äººçš„æ²»ç™‚

## å®‰å…¨æ€§è€ƒé‡
### å¸¸è¦‹å‰¯ä½œç”¨
- å—œç¡ã€é ­æšˆ
- ç–²å€¦
- å™å¿ƒ

### å„ªå‹¢
- å‰¯ä½œç”¨è¼ƒ levetiracetam è¼•å¾®
- è¡Œç‚º/ç²¾ç¥å‰¯ä½œç”¨ç™¼ç”Ÿç‡è¼ƒä½
- ç„¡éœ€åŠ‘é‡èª¿æ•´å³å¯é–‹å§‹ä½¿ç”¨ç›®æ¨™åŠ‘é‡

### è—¥ç‰©äº¤äº’ä½œç”¨
- èˆ‡ CYP2C19 ç›¸é—œä»£è¬
- rifampin å¯èƒ½é™ä½å…¶è¡€ä¸­æ¿ƒåº¦
- é¿å…èˆ‡é…’ç²¾ä½µç”¨




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šé¿å…å¤§é‡æ”å–ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šå¢å¼·ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶ä½œç”¨
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Depressive Disorder** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šAntiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indicat...

**Bronchial Spasm** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**è­‰æ“šç­‰ç´š**ï¼šL3 (å…‰æ•æ„Ÿæ€§ç™²ç™‡çš„è‡¨åºŠç ”ç©¶é–“æ¥æ”¯æŒ)

**å»ºè­°**ï¼š
1. å°æ–¼å…‰æ•æ„Ÿæ€§æˆ–è¦–è¦ºèª˜ç™¼æ€§ç™²ç™‡æ‚£è€…ï¼Œbrivaracetam æ˜¯åˆç†çš„æ²»ç™‚é¸æ“‡
2. å¯è€ƒæ…®å¾ levetiracetam è½‰æ›ï¼Œå°¤å…¶ç•¶æ‚£è€…æœ‰è¡Œç‚ºå‰¯ä½œç”¨æ™‚
3. å»ºè­°åŠ‘é‡ï¼šæˆäººæ¯æ—¥ 50-200 mgï¼Œåˆ†å…©æ¬¡æœç”¨

**ä¸‹ä¸€æ­¥ç ”ç©¶æ–¹å‘**ï¼š
- é‡å°è¦–è¦ºæ€§ç™²ç™‡äºå‹çš„å‰ç»æ€§è‡¨åºŠè©¦é©—
- è©•ä¼° brivaracetam èˆ‡å…¶ä»–ç¬¬ä¸‰ä»£æŠ—ç™²ç™‡è—¥ç‰©åœ¨æ­¤é©æ‡‰ç—‡çš„æ¯”è¼ƒæ•ˆç›Š
- æ”¶é›†çœŸå¯¦ä¸–ç•Œæ•¸æ“šä»¥æ”¯æŒé©æ‡‰ç—‡æ“´å±•

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tyrosine]({{ "/drugs/tyrosine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Metoprolol]({{ "/drugs/metoprolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Brivaracetamè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/brivaracetam/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_brivaracetam,
  title = {Brivaracetamè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/brivaracetam/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
